Published in Lancet on June 14, 2003
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04
Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res (2006) 3.04
Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol (2008) 2.47
von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet (2011) 2.45
Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol (2006) 2.25
Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer (2008) 2.11
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer (2008) 2.04
Structured assessment and followup for patients with hereditary kidney tumour syndromes. Can Urol Assoc J (2016) 2.01
Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol (2010) 1.76
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J (2008) 1.72
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol (2011) 1.70
Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol (2010) 1.67
Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med (2006) 1.66
The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ (2008) 1.61
Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev (2009) 1.57
von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med (2007) 1.52
Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res (2012) 1.49
Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev (2013) 1.47
The human side of hypoxia-inducible factor. Br J Haematol (2008) 1.41
A role for von Hippel-Lindau protein in pancreatic beta-cell function. Diabetes (2008) 1.33
Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32
The approach to the patient with paraganglioma. J Clin Endocrinol Metab (2009) 1.30
Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans Am Ophthalmol Soc (2005) 1.27
Neurologic manifestations of von Hippel-Lindau disease. JAMA (2008) 1.26
Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review. Retina (2007) 1.25
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep (2009) 1.25
Advances in the genetics of familial renal cancer. Oncologist (2010) 1.23
Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol (2013) 1.23
Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol (2008) 1.23
Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neuro Oncol (2009) 1.17
Hypoxic control of metastasis. Science (2016) 1.16
Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutation. FASEB J (2011) 1.14
Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem (2006) 1.13
Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol (2007) 1.11
Pituitary stalk hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2009) 1.10
Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease. Ophthalmology (2007) 1.10
The metabolic basis of kidney cancer. Semin Cancer Biol (2012) 1.09
Brachyury: a diagnostic marker for the differential diagnosis of chordoma and hemangioblastoma versus neoplastic histological mimickers. Dis Markers (2014) 1.08
Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol (2012) 1.04
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int (2009) 1.03
Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease. World J Gastroenterol (2010) 1.03
Targeted therapies for non-clear renal cell carcinoma. Target Oncol (2010) 1.02
Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease. Nucl Med Mol Imaging (2012) 1.02
Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease. Mol Vis (2005) 1.00
Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Mol Cell Biol (2008) 1.00
Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis (2014) 0.99
The von Hippel-Lindau gene: turning discovery into therapy. Cancer (2008) 0.97
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther (2008) 0.96
Von hippel-lindau disease: a new approach to an old problem. Int J Endocrinol Metab (2012) 0.96
Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther (2009) 0.96
Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Rep (2013) 0.96
Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician. Eur J Pediatr (2011) 0.96
Attitude towards pre-implantation genetic diagnosis for hereditary cancer. Fam Cancer (2009) 0.95
Tumor derived vasculogenesis in von Hippel-Lindau disease-associated tumors. Sci Rep (2014) 0.95
Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2014) 0.94
Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype. Invest Ophthalmol Vis Sci (2010) 0.94
Nephron-sparing surgery for multifocal and hereditary renal tumors. Curr Opin Urol (2014) 0.94
Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes Cancer (2011) 0.94
Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet (2015) 0.94
The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des (2009) 0.93
Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer (2006) 0.93
Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol Ther (2010) 0.93
Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol (2012) 0.93
Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms. Oncogene (2011) 0.92
Disseminated hemangioblastomatosis of the central nervous system without von Hippel-Lindau disease: a case report. J Korean Med Sci (2009) 0.92
Developmental function of Nm23/awd: a mediator of endocytosis. Mol Cell Biochem (2009) 0.92
A central role for hypoxic signaling in cartilage, bone, and hematopoiesis. Curr Osteoporos Rep (2011) 0.90
Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease. J Pathol (2008) 0.89
Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem (2008) 0.89
Paragangliomas/Pheochromocytomas: clinically oriented genetic testing. Int J Endocrinol (2014) 0.89
Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling. Cancer Res (2008) 0.89
Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol (2016) 0.89
Von Hippel-Lindau disease. Handb Clin Neurol (2015) 0.89
Early microsurgical treatment for spinal hemangioblastomas improves outcome in patients with von Hippel-Lindau disease. Surg Neurol Int (2012) 0.89
Renal cancer: oxygen meets metabolism. Exp Cell Res (2012) 0.88
Ocular von Hippel-Lindau disease: clinical update and emerging treatments. Curr Opin Ophthalmol (2008) 0.88
VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL. J Biol Chem (2009) 0.88
VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis. Am J Pathol (2010) 0.87
Retinal vascular proliferation as an ocular manifestation of von Hippel-Lindau disease. Arch Ophthalmol (2008) 0.87
First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. Fam Cancer (2015) 0.87
Ubiquitin domain proteins in disease. BMC Biochem (2007) 0.86
Long-term outcome after resection of brainstem hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2010) 0.86
Von Hippel-Lindau syndrome: demonstration of entire disease spectrum with (68)Ga-DOTANOC PET-CT. Korean J Radiol (2014) 0.86
Hereditary renal cell carcinoma associated with von Hippel-Lindau disease: a description of a Nova Scotia cohort. Can Urol Assoc J (2009) 0.86
Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease. Ophthalmology (2006) 0.85
Sunitinib treatment for metastatic renal cell carcinoma in patients with von hippel-lindau disease. Cancer Res Treat (2013) 0.85
Clinical characteristics of renal cell carcinoma in Korean patients with von Hippel-Lindau disease compared to sporadic bilateral or multifocal renal cell carcinoma. J Korean Med Sci (2009) 0.85
Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Expert Opin Drug Discov (2008) 0.85
Supratentorial hemangioblastoma: clinical features, prognosis, and predictive value of location for von Hippel-Lindau disease. Neuro Oncol (2012) 0.84
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery (2011) 0.84
Upregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal hemangioblastoma. Graefes Arch Clin Exp Ophthalmol (2014) 0.84
Pituitary stalk hemangioblastoma in a von hippel-lindau patient : clinical course follow-up over a 20-year period. J Korean Neurosurg Soc (2013) 0.84
Developmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau disease. Mod Pathol (2011) 0.84
Pancreatic cystic neoplasms: a review of preoperative diagnosis and management. J Zhejiang Univ Sci B (2013) 0.84
Long-term follow-up clinical courses of cerebellar hemangioblastoma in von hippel-lindau disease : two case reports and a literature review. J Korean Neurosurg Soc (2010) 0.84
Genetic signature for human risk assessment: lessons from trichloroethylene. Environ Mol Mutagen (2009) 0.84
Human variation databases. Database (Oxford) (2010) 0.84
Genetic basis of bilateral renal cancer: implications for evaluation and management. J Clin Oncol (2009) 0.83
An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma. Hum Mol Genet (2014) 0.83
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol (2005) 3.74
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
Prevention of intraoperative cerebrospinal fluid leaks by lumbar cerebrospinal fluid drainage during surgery for pituitary macroadenomas. J Neurosurg (2012) 3.35
Age-related macular degeneration. Lancet (2008) 3.34
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res (2005) 3.03
The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol (2007) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer (2012) 2.95
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88
The emerging biology of the nitrite anion. Nat Chem Biol (2005) 2.88
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Posterior subtemporal transtentorial approach to intraparenchymal lesions of the anteromedial region of the superior cerebellum. J Neurosurg (2005) 2.69
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
Pathophysiology of persistent syringomyelia after decompressive craniocervical surgery. Clinical article. J Neurosurg Spine (2010) 2.49
Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA (2005) 2.47
Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation (2007) 2.46
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet (2009) 2.40
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg (2003) 2.34
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol (2009) 2.27
Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol (2010) 2.26
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med (2007) 2.19
Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res (2007) 2.17
Retrospective analysis of a concurrent series of microscopic versus endoscopic transsphenoidal surgeries for Knosp Grades 0-2 nonfunctioning pituitary macroadenomas at a single institution. J Neurosurg (2014) 2.13
The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol (2007) 2.12
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell (2011) 2.12
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10
Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet (2013) 2.09
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet (2010) 2.06
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 2.04
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab (2006) 2.04
The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J (2004) 2.04
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol (2013) 1.96
The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol (2008) 1.93
Pathophysiology of primary spinal syringomyelia. J Neurosurg Spine (2012) 1.92
Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.92
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol (2007) 1.86
Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med (2009) 1.83
Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci (2008) 1.83
Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene (2008) 1.82
Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem (2008) 1.81
Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg (2002) 1.79
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat (2004) 1.78
Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem (2004) 1.76
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes. J Urol (2010) 1.74
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA (2007) 1.73
An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies. Int J Cancer (2013) 1.71
Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst (2006) 1.70
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
Retracted Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease. Neurosurgery (2009) 1.69
Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg (2007) 1.68
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol (2010) 1.67
Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina (2009) 1.67
Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. Mod Pathol (2004) 1.67
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67